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embolism in an immunocompetent patient with
acute cytomegalovirus infection: a case report
Yves Marie Vandamme1,4*, Alexandra Ducancelle2, Loïc Biere3, Nathalie Viot3, Frédéric Rouleau3,
Valérie Delbos1 and Pierre Abgueguen1Abstract
Background: Primary acute cytomegalovirus infection in immunocompetent patients is common worldwide.
Infection is most often asymptomatic or occurs sub-clinically with a self-limited mononucleosis-like syndrome. More
rarely, the infection may lead to severe organ complications with pneumonia, myocarditis, pericarditis, colitis and
hemolytic anemia. Recent cases of cytomegalovirus-associated thrombosis have also been reported sporadically in
the medical literature.
Case presentation: We report here a case of simultaneous myopericarditis and pulmonary embolism in a 30-year-old
man with no medical history. The patient was not immunocompromised. We discuss the possible role of acute
cytomegalovirus infection in the induction of vascular damage and review relevant cases in the literature.
Conclusion: Thrombosis in patients with acute cytomegalovirus infection may be more frequent than is generally
thought. Physicians need to be aware of the possible association between acute cytomegalovirus and thrombosis in
immunocompetent patients, especially in the presence of severe systemic infection, as our case illustrates.
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Primary cytomegalovirus (CMV) infection is common
worldwide. The infection usually occurs early in life and
then lies dormant. The resulting seroprevalence among
adults varies from 40 to 100% depending on the country,
socioeconomic conditions and patient age [1-3].
In immunocompetent patients, primary infection is
usually asymptomatic or occurs subclinically with a self
limited mononucleosis-like syndrome. Prolonged fever,
myalgia, headache, cervical lymphadenopathy, spleno-
megaly, rash and nonspecific constitutional symptoms are
common and may persist for weeks [4]. Very occasionally,
CMV can cause tissue-invasive end-organ damage and
complications including pneumonia [5], myocarditis [6],
hemolytic anemia [7], retinitis [8], colitis [9] and hepatitis* Correspondence: ymvandamme@chu-angers.fr
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distribution, and reproduction in any medium[10]. Central nervous system involvement with meningitis,
encephalitis and Guillain-Barré syndrome may also be ob-
served albeit rarely [11,12].
More recently, primary CMV infection has been associ-
ated with venous thrombosis. To date, the medical litera-
ture counts close to 100 articles on this association, mainly
in case reports and additionally in several small series of
patients [13]. Thrombosis has been historically considered
as an extremely rare complication of acute CMV infection.
However, two recent studies found incidences ranging
from 6.4% and 7.9%, suggesting that thrombosis in patients
with acute CMV infection may be more common than
previously thought [14,15].
We describe here a severe acute CMV infection with
myopericarditis and pulmonary embolism. We also review
relevant cases in the literature to alert physicians on the
possibility of thrombotic events in CMV-infected im-
munocompetent individuals. We also discuss mechanisms
that may explain the role of CMV in thrombosis.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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A 30-year-old caucasian man was admitted to the cardiac
intensive care unit on 27 February 2010 for a two-day his-
tory of left precordial chest pain. The patient had no par-
ticular medical history other than an episode of viral
gastroenteritis that resolved favorably three weeks before
his hospitalization. His temperature was 38°C (100.4°F),
heart rate 86 beats per minute (BPM), and blood pressure
122/86 mmHg at admission. He described typical pericardi-
tis symptoms with substernal and precordial chest pain re-
lieved by sitting up and bending forward and worsened by
lying down and breathing in. There was no radiating pain
and physical examination was normal without friction rub.
Other symptoms included fatigue and anxiety. White blood
cells (WBC) count was 10,250 cells/mm3 with 7,240 neu-
trophils/mm3 and 1,410 lymphocytes/mm3, hemoglobin
was 153.0 g/L with a platelet count of 167,000/mm3. His
C-reactive protein level was 33 mg/L (normal < 3 mg/l).
Cardiac enzyme tests showed a highly elevated level of
troponin Ic at 3.51 μg/L. Alanine aminotransferase (ALT)
was at 50 U/L, aspartate aminotransferase (AST) at 202 U/
L and creatine kinase (CK) at 2,275 U/L. The electrocardio-
gram showed a 12-lead diffuse, concave ST segment eleva-
tion without low-voltage QRS complexes. Transthoracic
echocardiography found a normal left ventricular volume
with no kinetic disorder or pericardial effusion. Magnetic
resonance imaging (MRI) confirmed myopericarditis with a
hyper-intense signal on the MRI late gadolinium enhance-
ment (Figure 1). The chest pain regressed rapidly, the
troponin Ic level decreased and the patient was discharged
to home four days later with a medical treatment compris-
ing a combination of colchicine 1 mg per day and acetyl-
salicylic acid 3 g per day for one month.
Three days later, the patient remained febrile (40°C)
and presented with a painful right chest with dyspnea.
He was readmitted to the cardiac intensive care unit.Figure 1 Typical magnetic resonance imaging image of
myocarditis. This figure shows a magnetic resonance imaging four
chamber cardiac view. Mid-wall late gadolinium enhancement of
the lateral wall is visible (arrows). This is a common MRI aspect of
myocarditis.His temperature was 37.4°C (99.32°F), his heart rate 74
BPM and blood pressure 134/78 mmHg. WBC count
was 14,190 cells/mm3, with 3,830 neutrophils/mm3 and
8,370 lymphocytes/mm3 with 2% of the lymphocytes
presenting a large hyperbasophilic form. The C-reactive
protein level was 100 mg/L. Cardiac enzymes tests
showed a normalization of troponin Ic < 0.01 μg/L and
CK level of 58 U/L but liver function tests revealed an
ALT level of 299 U/L and an AST level of 133 U/L. The
electrocardiogram showed the disappearance of ST seg-
ment elevation without PR segment depression and the
echocardiography was unchanged. Bloody sputum sug-
gested a pulmonary embolism. Chest x-ray showed no
opacity on the pulmonary field and the diagnosis was
confirmed with a computed tomography (CT) scan
showing a bilateral pulmonary embolism of moderate
severity with signs of pulmonary infarction. Treatment
with intravenous heparin was initiated. Because of the
mononucleosis-like biological syndrome, hepatitis virus
serology was performed. The results of serological tests
for human immunodeficiency virus (HIV) enzyme-
linked immunosorbent assay (ELISA), hepatitis A virus
IgM, hepatitis B surface antigen, hepatitis C virus,
Epstein-Barr virus and toxoplasma IgM antibodies were
all negative. For CMV however, ELISA tests were strongly
positive for IgM and equivocal for IgG on the first tests
performed 7 days after hospital admission. Also at Day 7,
quantitative CMV deoxyribonucleic acid (DNA) polymer-
ase chain reaction (PCR) was positive with 2050 CMV
DNA copies/mL (ARGENE CMV R-gene™, Biomerieux,
France). Of note: CMV PP65 antigen was negative at Day
14. The evolution of the CMV tests is presented in
Table 1.
The fever disappeared 5 days after the second admission
with no anti-CMV therapy. The patient presented no fur-
ther chest pain. He felt very tired for two months. Hepatitis
was at its maximum 10 days after the second admission but
liver tests returned to normal after one month. Heparin
was replaced by six months of fluindione. The coagulation
work-up included prothrombin time and tests for activated
protein C resistance, antithrombin activity, and proteins C
and S, as well as an assay for anticardiolipin and anti-beta 2
glycoprotein-1 antibodies. All results were normal.
Discussion
Acute CMV infection in immunocompetent patients is
common worldwide but symptoms remain subclinical
most of the time. Rarely, patients may develop a severe in-
fection that manifests with multiple organ involvement
and marked constitutional symptoms. Serious CMV infec-
tion is more well-known and more frequently described in
immunocompromised patients, including in particular
transplantation recipients and people with untreated ac-
quired immunodeficiency syndrome (AIDS), where CMV
Table 1 Evolution of cytomegalovirus tests
Day 7 after admission Day 14 after admission Day 28 after admission
Elisa (CMV Axsym-Abbott)
Ig M (negative: ratio < 0.4) 1.003 5.852 7.667
Ig G (negative: level < 15UA/ml) 15.2 51.3 165.7
PP65 antigen - Negative -
CMV DNA real-time PCR (copies/mL) (detection range: 150 copies/ml) 2050 7000 <150




PCR: polymerase chain reaction.
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an immunocompetent patient with pulmonary embol-
ism and myopericarditis, two rare and severe CMV in-
fection complications.
Pericarditis and myocarditis in immunocompetent pa-
tients with acute CMV have been described for years now
in the literature [16-18]. CMV has a wide tissue tropism
and is able to infect multiple organs including the heart.
However, clinically significant cardiac disease is rarely re-
ported overall, although we note an increase of such case-
reports in the literature in recent years [19-23] and think
that the association may be under-diagnosed currently.
Monitoring of serum antibody levels, which provides a
picture of viral pericarditis, is often not performed despite
the recommendation to do so in European Society of Car-
diology (ESC) guidelines on pericardial diseases [24]. In-
deed, an association between CMV and myocarditis was
described in a study of more than 1100 patients with ac-
tive and borderline myocarditis [25]. In that study, PCR of
heart samples revealed CMV DNA in 3% of the patients.
In another population-based study of immunocompetent
patients with fatal myocarditis, CMV DNA was the most
common single finding: viral genome was detected by
PCR in the cardiac samples of 15 patients (38%), and in
67% of the patients for whom PCR was CMV-positive, in
situ hybridization revealed viral DNA in cardiomyocytes
[6]. We believe that the development or the aggravation of
an acute hepatitis after an obvious clinical improvement of
myocarditis and a decrease in cardiac necrosis markers, as
noted in several reports, could be suggestive of an acute
CMV infection [19,22].
Also, chest pain and heart failure are not obligatory clin-
ical features of myopericarditis. In a series of 115 hospital-
ized immunocompetent patients with diagnosis of primary
CMV infection, the authors found two cases of pericarditis
for which the diagnosis was established as a fortuitous
finding on routine electrocardiograms in patients without
chest pain [26]. Another case report presented an im-
munocompetent patient with no signs or symptoms of car-
diac inflammation. Myocarditis was incidentally diagnosed
on trans-thoracic echocardiography, which was undertakento search for an infectious endocarditis in the setting of a
prolonged fever [21].
In recent case-reports, the diagnosis of myocarditis
was aided by the presence of clinical signs of pericarditis
and cardiac investigations including myocardial necrosis
markers and echocardiography [19,22,23]. In our case,
the suspicion of heart involvement led us to perform an
MRI that confirmed the diagnosis of myopericarditis. The
diagnosis of acute CMV infection was confirmed by anti-
bodies in the plasma and the evolution of CMV viral load.
Of interest: CMV PP65 antigenemia was negative for our
patient. This may be explained by a lesser sensitivity for
CMV antigenemia compared to CMV PCR assay, as has
been described in the literature, albeit generally in the set-
ting of solid organ or bone marrow transplant patients
[27,28]. It may also be explained by the fact that antigene-
mia was performed only once at Day14; thus it is possible
that antigenemia was not yet positive or had already
disappeared.
The association of CMV infection and vascular throm-
bosis was first described in immunocompromised patients,
especially in AIDS cases or after transplantation [29-31]. In
immunocompetent patients, CMV infection was first de-
scribed as a risk for coronary thrombotic events after stent
placement [32,33]. CMV-associated thrombosis was later
reported sporadically in immunocompetent adults with no
medical history only in case reports or in small series [13].
However, in two recent studies, the incidence of thrombosis
among patients with acute CMV infection was reported to
range from 6.4 to 7.9%, suggesting that it may not be so
rare after all [15,34]. In a prospective study comparing 187
hospitalized patients with deep vein thrombosis and/or pul-
monary embolism to 187 controls without thrombosis, the
incidence of acute CMV infection was 9.1% for the former
compared to 1.6% for the latter (odds ratio = 6.12; p =
0.016) [35]. In another recent case–control study on 397
consecutive patients with suspected deep vein thrombosis,
five were positive for CMV DNA whereas none were in the
control group [36]. In that study, all five of the CMV-
positive patients were women, below 37 years of age, with
another acquired risk for venous thrombosis.
Vandamme et al. BMC Research Notes 2014, 7:193 Page 4 of 5
http://www.biomedcentral.com/1756-0500/7/193Several hypotheses have been forwarded for the role of
CMV in inducing vascular damage. Squizzato et al. per-
formed a literature review focused on the effects of CMV
infection on coagulation [37]. CMV probably plays a differ-
ent role in inducing arterial or venous thrombosis. CMV
may induce transient antiphospholipid antibody production
[38] and certain strains may also express constitutively
phosphatidylserine (PS)-like procoagulant activity. Suther-
land et al. demonstrated that tissue factor (TF) antigen, a
coagulation initiator, could be identified on CMV using
monoclonal antibodies with flow cytometry and electron
microscopy [39]. However these properties were not unique
for CMV; they were also pertinent for other herpes viruses.
Moreover, CMV causes membrane perturbation when it in-
fects endothelial cells and activates a pro-coagulation state.
Von Willebrand factor (vWf) has been shown to be re-
leased during CMV infection [40], and, among 39 patients
with recent kidney transplantation and acute CMV infec-
tion, increased vWf and soluble vascular cell adhesion mol-
ecule 1 (sVCAM-1) in the peripheral blood were correlated
with viral infection [41].
Regarding the development of atherosclerosis and re-
stenosis, smooth muscle cell proliferation and migration
are crucial events. It has been suggested that one of the im-
mediate early gene products of CMV, IE84, binds to and
inhibits P53 transcriptional activity, thus inhibiting P53-
mediated apoptosis, which in turn permits smooth muscle
cell proliferation [42,43]. Moreover, CMV infection in-
creases PDGF b-receptor expression, which modulates
smooth muscle cell migration [44]. Also, CMV infection
may contribute to vascular effects in atherosclerotic plaque
inflammation by increasing levels of several cytokines with
inflammatory properties [45]. Especially, a modest increase
in interleukin (IL) 6 is observed in infected endothelial cells
[46]. CMV infection of endothelial cells also increases the
expression of CD40 [47], a protein present on atheroma-
associated cells and possibly involved in a number of pro-
cesses responsible for lesion progression and plaque
destabilization [48].
Our case-report underlines the interest of CMV serology
in the presence of viral myopericarditis. This complication
is infrequently reported in the literature but needs to be
kept in mind as it may lead to disproportionate aggression
to the myocardium and clinical heart failure. Our experi-
ence also illustrates the interest of MRI in the diagnosis of
myocarditis. Furthermore, the complication may indicate
a serious acute CMV infection capable of provoking other
serious complications such as vascular thrombosis and
pulmonary embolism.
Conclusion
In conclusion, to our knowledge, the present case is the
first to report acute CMV myopericarditis appearing with
a thrombotic pulmonary embolism. Physicians must keepthis association between severe CMV infection and vascu-
lar thrombosis in mind to better implement preventative
measures.
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